Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria: 1. Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Ethics Committee (IRB/EC); 2. Is between the ages of 18 and 75 years old, inclusive; 3. Has histologically or cytologically confirmed stage IIIB (malignant pericardial or pleural effusion) or stage IV non-small cell lung cancer; 4. Has non-squamous, non-small cell lung cancer 5. Has measurable disease, defined as at least one tumor that fulfills the criteria for a target lesion according to RECIST; 6. Has an ECOG performance status of 0 or 1; 7. Has a life expectancy of \> 3 months; 8. Has adequate hematologic function as evidenced by: 1. ANC ≥ 1,500/μL 2. PLT ≥ 100,000/μL 3. HGB ≥ 9 g/dL obtained within 1 week prior to the first dose of study medication; 9. Has adequate renal function as evidenced by: 1. Serum creatinine ≤ 1.5 X the upper limit of normal (ULN) for the reference lab 2. Urine dipstick for proteinuria of \< 1+ (i.e., either 0 or trace) within 2 weeks of Day 1 If urine dipstick is ≥ 1+, then urine protein excretion must be ≤ 500 mg over a 24 hour collection obtained within 1 week prior to the first dose of study medication; 10. Has adequate hepatic function as evidenced by: 1. Serum total bilirubin ≤ 1.0 mg/dL 2. AST ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases) 3. ALT ≤ 2.5X ULN for the reference lab (≤ 5X ULN for subjects with known hepatic metastases) obtained within 1 week prior to the first dose of study medication; 11. Has adequate coagulation function as evidenced by: 1. INR ≤ 1.5 2. PTT ≤ ULN for the reference lab obtained within 1 week prior to the first dose of study medication; 12. If a woman of childbearing potential or a fertile man (and his partners), must agree to use an effective form of contraception (hormonal contraceptive, double-barrier method or abstinence) during the study. Exclusion Criteria: 1. Has received prior systemic chemotherapy at any time for lung cancer; 2. Has received previous radiation therapy to \>30% of active bone marrow or any radiation therapy within 3 weeks of Day 1; 3. Has a known hypersensitivity to baker's yeast, or has an active yeast infection; 4. Has had previous exposure to Betafectin® or Imprime PGG; 5. Has an active infection; 6. Presents with any of the following medical diagnoses/conditions at the time of screening: 1. Central nervous system (CNS) metastases 2. Uncontrolled hypertension (\>150/100 mmHg) or hypertension that requires \> two agents for adequate control 3. Peripheral neuropathy ≥ grade 2 from any cause 4. Fever of \>38.5° C within 3 days prior to screening or Day 1, initial dosing 5. Known HIV/AIDs, Hepatitis B, Hepatitis C, connective tissue or autoimmune disease, or other clinical diagnosis, ongoing or intercurrent illness that in the physician's opinion could interfere with participation 7. Has a history of any of the following medical diagnoses/conditions: 1. Arterial or venous thromboembolic or hemorrhagic disorders including stroke, transient ischemic attack or cerebral infarction 2. Deep vein thrombosis within 1 year prior to screening 3. Myocardial infarction or an unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure) within the previous 6 months 4. Second malignancy within the previous 5 years, other than basal cell carcinoma, cervical intra-epithelial neoplasia or curatively treated prostate cancer with a PSA of \<2.0 ng/mL 8. Has a known hypersensitivity to bevacizumab, murine proteins, or any component of bevacizumab; 9. Has a know sensitivity to polyethoxylated castor oil; 10. Has previously received treatment with bevacizumab; 11. Has had surgery within 4 weeks of Day 1 or needle or open biopsy within 1 week of Day 1; 12. Has a non-healing wound or gastric ulcer; 13. Has a non-healed bone fracture; 14. Is receiving systemic anti-coagulation therapy (e.g., dipyridalmole (Persantine®), ticlopidine (Ticlid®), clopidogrel (Plavix®) and /or cilostazol (Pletal®); 15. Is receiving chronic daily treatment with aspirin (\>100 mg/day) or other nonsteroidal anti-inflammatory agents known to inhibit platelet function within 1 week of Day 1; 16. Presents with any of the following medical diagnoses/conditions at the time of screening: a. Predominant squamous cell histology 17. Has a history of any of the following medical diagnoses/conditions: 1. Hemoptysis (≥ ½ tsp red blood) 2. Bleeding diathesis or coagulopathy 18. If female, is pregnant or breast-feeding; 19. Is receiving concurrent investigational therapy or has received investigational therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication); 20. Has previously received an organ or progenitor/stem cell transplant.